Organon Mircette
Executive Summary
April 22 press release announcing FDA approval of oral contraceptive Mircette implies broader than approved claims. Release implies that because of the treatment regimen's hormone-free days, women "experiencing menstrual migraines and other inter-menstrual side effects such as dysmenorrhea and pre-menstrual syndrome" will be helped. Mircette "is not indicated for these conditions," FDA notes. Press release also implies that Mircette is superior to other OCs because of the hormone free period. "There is no known clinically significant effect of the period of hormone free-days," FDA states
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth